ClinicalTrials.gg
CompletedNCT03523585Updated Feb 27, 2026Results posted

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

A Phase 3 interventional study of Trastuzumab deruxtecan and Capecitabine in Breast Cancer, sponsored by Daiichi Sankyo. Completed at 227 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
608
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
5th of 58
608 · median 139
Started
2018
with 5 others
Phase 3
12 of 58
3 open now
Registered
4th of 58
by date
Lead sponsor
9 of 58
Daiichi Sankyo

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 5th largest by enrollment, is one of 6 that started in 2018, is one of 12 in phase 3, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will compare DS 8201a to standard treatment.

Participants must have HER2 breast cancer that has been treated before.

Their cancer:

  • cannot be removed by an operation
  • has spread to other parts of the body
Read the detailed description

The study is designed to compare DS 8201a versus standard of care (investigator's choice) in subjects with unresectable and/or metastatic breast cancer previously treated with T-DM1.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Metastatic breast cancer
  • DS 8201a
  • DESTINY - Breast 02
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is the age of majority in their country
  • Has documented breast cancer that:

    1. is unresectable or
    2. has confirmed -positive expression as determined according to American Society of Clinical Oncology - College of American Pathologists guidelines evaluated at a central laboratory
    3. was previously treated with ado-trastuzumab emtansine (T-DM1)
  • Has documented radiologic progression (during or after most recent treatment or within 6 months after completing therapy)
  • Is HER2 positive as confirmed by central laboratory assessment of most recent tumor tissue sample available. If archived tissue is not available, agrees to provide a fresh .
  • Male and female participants of reproductive/ must agree to use a highly effective form of or avoid intercourse during and upon completion of the study and for at least:

    1. 7 months after the last dose of DS-8201a (females); 4.5 months after last dose of DS-8201a (males)
    2. 6 months after the last dose of lapatinib/capecitabine for female participants (3 months for male participants)
    3. 7 months after the last dose of trastuzumab/capecitabine
  • Has adequate hematopoietic, renal and hepatic functions

Exclusion criteria

Exclusion Criteria:

  • Has previously participated in an antibody drug conjugate study sponsored by Daiichi Sankyo. Prior treatment in the /neo-adjuvant setting would be allowed if progression of disease did not occur within 12 months of end of adjuvant therapy
  • Has had prior treatment with capecitabine
  • Has uncontrolled or significant cardiovascular disease
  • Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required , has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  • Has active central nervous system (CNS)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
608 participants (actual)

Study arms

  • Experimental
    Trastuzumab deruxtecan (DS-8201a)

    HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a

    Drug: Trastuzumab deruxtecan

  • Active comparator
    Trastuzumab+capecitabine

    HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine

    Drug: Capecitabine · Drug: Trastuzumab

  • Active comparator
    Lapatinib+capecitabine

    HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine

    Drug: Capecitabine · Drug: Lapatinib

Interventions

  • DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose

    Also known as: DS-8201a, T-DXd

  • Investigator's choice Standard of Care when combined with trastuzumab or lapatinib

    Also known as: Investigator's Choice Comparative Therapy

  • Investigator's choice Standard of Care when combined with capecitabine

    Also known as: Investigator's Choice Comparative Therapy

  • Investigator's choice Standard of Care when combined with capecitabine

    Also known as: Investigator's Choice Comparative Therapy

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

    Progression-free survival (PFS) by BICR was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.

    Time frame: Baseline up to 46 months postdose

Secondary outcomes

  1. Overall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

    Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there is no death reported for a subject before the data cutoff for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive.

    Time frame: Baseline up to 46 months postdose

  2. Percentage of Participants With Objective Response Rate (ORR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

    The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on BICR and Investigator Assessment is reported.

    Time frame: Baseline up to 46 months postdose

  3. Duration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

    Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.

    Time frame: Baseline up to 46 months postdose

  4. Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

    Progression-free survival (PFS) by investigator assessment was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.

    Time frame: Up to 46 months

07

Results

Posted Jun 26, 2023

Participant flow

A total of 608 participants were enrolled at study sites in 15 countries. Primary results reported is from first participant randomized up to data cut-off date of 30 Jun 2022. The results presented are based on primary analysis up to 46 months.

Participant flow — Overall Study
MilestoneTrastuzumab Deruxtecan (T-DXd)Trastuzumab+CapecitabineLapatinib+Capecitabine
Started40691111
Randomized40691111
Randomized but not treated243
Completed9414
Not completed31290107
Withdrew: Progressive disease1746477
Withdrew: Adverse event7459
Withdrew: Withdrawal by subject30116
Withdrew: Clinical progression23510
Withdrew: Death401
Withdrew: Physician decision210
Withdrew: Lost to follow-up100
Withdrew: Miscellaneous100
Withdrew: Protocol deviation101
Withdrew: Randomized but not treated243

Outcome measures

PrimaryProgression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

Progression-free survival (PFS) by BICR was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.

Time frame:
Baseline up to 46 months postdose
Reported as:
Median · months
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
monthsTrastuzumab Deruxtecan (T-DXd)Treatment of Investigator's/Physician's Choice (TPC)
Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine17.8 (14.3 to 20.8)6.9 (5.5 to 8.4)
Statistical analysis
  • Trastuzumab Deruxtecan (T-DXd) vs Treatment of Investigator's/Physician's Choice (TPC) · Log Rank · p = <0.000001 (Stratified Log-rank p-value) · Hazard ratio (hr): 0.3589 · 95% CI 0.2840 to 0.4535Hazard Ratio based on stratified Cox proportional hazards model with stratification factors: hormone receptor status, prior treatment with pertuzumab, and history of visceral disease, as defined by the IXRS.
SecondaryOverall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there is no death reported for a subject before the data cutoff for OS analysis, OS will be censored at the last contact date at which the subject is known to be alive.

Time frame:
Baseline up to 46 months postdose
Reported as:
Median · months
Overall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
monthsTrastuzumab Deruxtecan (T-DXd)Treatment of Investigator's/Physician's Choice (TPC)
Overall Survival (OS) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine39.2 (32.7 to NA)26.5 (21.0 to NA)
Statistical analysis
  • Trastuzumab Deruxtecan (T-DXd) vs Treatment of Investigator's/Physician's Choice (TPC) · Log Rank · p = 0.0021 (Stratified Log-rank p-value) · Hazard ratio (hr): 0.6575 · 95% CI 0.5023 to 0.8605Hazard Ratio based on stratified Cox proportional hazards model with stratification factors: hormone receptor status, prior treatment with pertuzumab, and history of visceral disease, as defined by the IXRS.
SecondaryPercentage of Participants With Objective Response Rate (ORR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

The Objective Response Rate (ORR) was defined as the percentage of participants who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), assessed by BICR and investigator assessment based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Confirmed ORR based on BICR and Investigator Assessment is reported.

Time frame:
Baseline up to 46 months postdose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response Rate (ORR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Percentage of ParticipantsTrastuzumab Deruxtecan (T-DXd)Treatment of Investigator's/Physician's Choice (TPC)
BICR69.7 (65.0 to 74.1)29.2 (23.0 to 36.0)
Investigator Assessment74.1 (69.6 to 78.3)26.7 (20.8 to 33.4)
Statistical analysis
  • Trastuzumab Deruxtecan (T-DXd) vs Treatment of Investigator's/Physician's Choice (TPC) · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel test adjusted for stratification factors: hormone receptor status, prior treatment with pertuzumab, and history of visceral disease, as defined by the IXRS.)
  • Trastuzumab Deruxtecan (T-DXd) vs Treatment of Investigator's/Physician's Choice (TPC) · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel test adjusted for stratification factors: hormone receptor status, prior treatment with pertuzumab, and history of visceral disease, as defined by the IXRS.)
SecondaryDuration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

Duration of Response (DoR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR in participants with confirmed CR/PR based on BICR and investigator assessment is reported.

Time frame:
Baseline up to 46 months postdose
Reported as:
Median · months
Duration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
monthsTrastuzumab Deruxtecan (T-DXd)Treatment of Investigator's/Physician's Choice (TPC)
Duration of Response (DoR) Based on BICR in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine19.6 (15.9 to NA)8.3 (5.8 to 9.5)
SecondaryProgression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

Progression-free survival (PFS) by investigator assessment was defined as the time from the date of randomization to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause.

Time frame:
Up to 46 months
Reported as:
Median · months
Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
monthsTrastuzumab Deruxtecan (T-DXd)Treatment of Investigator's/Physician's Choice (TPC)
Progression-Free Survival (PFS) Based on Investigator Assessment in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine16.7 (14.3 to 19.6)5.5 (4.4 to 7.0)
Statistical analysis
  • Trastuzumab Deruxtecan (T-DXd) vs Treatment of Investigator's/Physician's Choice (TPC) · Log Rank · p = <0.000001 (Stratified Log-rank p-value.) · Hazard ratio (hr): 0.2828 · 95% CI 0.2270 to 0.3524Hazard Ratio based on stratified Cox proportional hazards model with stratification factors: hormone receptor status, prior treatment with pertuzumab, and history of visceral disease, as defined by the IXRS.

Adverse events

Collected over Adverse events (AE) were collected from the date of signing the informed consent form up to 47 days after last dose of the study drug, up 46 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab Deruxtecan (T-DXd)143/406 (35.2%)103/404 (25.5%)398/404 (98.5%)
Trastuzumab+Capecitabine40/91 (44%)19/87 (21.8%)79/87 (90.8%)
Lapatinib+Capecitabine46/111 (41.4%)27/108 (25%)102/108 (94.4%)
Most frequent serious events
Showing 10 of 130
Most frequent serious events
EventTrastuzumab Deruxtecan (T-DXd)Trastuzumab+CapecitabineLapatinib+Capecitabine
DiarrhoeaGastrointestinal disorders3/4043/871/108
Abdominal PainGastrointestinal disorders2/4043/870/108
Disease ProgressionGeneral disorders1/4041/873/108
Pleural EffusionRespiratory, thoracic and mediastinal disorders2/4041/873/108
PneumonitisRespiratory, thoracic and mediastinal disorders10/4040/871/108
VomitingGastrointestinal disorders6/4042/870/108
NauseaGastrointestinal disorders5/4042/870/108
PneumoniaInfections and infestations6/4040/871/108
PyrexiaGeneral disorders3/4041/870/108
GastroenteritisInfections and infestations1/4041/871/108
Most frequent other events
Showing 10 of 57
Most frequent other events
EventTrastuzumab Deruxtecan (T-DXd)Trastuzumab+CapecitabineLapatinib+Capecitabine
NauseaGastrointestinal disorders292/40429/8744/108
DiarrhoeaGastrointestinal disorders109/40433/8769/108
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders7/40448/8752/108
VomitingGastrointestinal disorders150/4049/8714/108
AlopeciaSkin and subcutaneous tissue disorders150/4044/874/108
FatigueGeneral disorders144/40420/8732/108
ConstipationGastrointestinal disorders142/40412/879/108
Decreased AppetiteMetabolism and nutrition disorders124/40415/8720/108
AnaemiaBlood and lymphatic system disorders114/40413/8713/108
AstheniaGeneral disorders97/4046/8713/108

Baseline characteristics

Baseline characteristics were assessed using the Full Analysis Set.

Age, Categorical
Age, Categorical(Participants)Trastuzumab Deruxtecan (T-DXd)Trastuzumab+CapecitabineLapatinib+CapecitabineTotal
<=18 years0000
Between 18 and 65 years3217391485
>=65 years851820123
Age, Continuous
Age, Continuous(years)Trastuzumab Deruxtecan (T-DXd)Trastuzumab+CapecitabineLapatinib+CapecitabineTotal
Mean54.6 ± 11.9955.7 ± 11.4054.6 ± 11.0654.8 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab Deruxtecan (T-DXd)Trastuzumab+CapecitabineLapatinib+CapecitabineTotal
Female40389111603
Male3205
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trastuzumab Deruxtecan (T-DXd)Trastuzumab+CapecitabineLapatinib+CapecitabineTotal
American Indian or Alaska Native2002
Asian1222036178
Native Hawaiian or Other Pacific Islander0011
Black or African American102517
White2576661384
More than one race0000
Unknown or Not Reported153826
Region of Enrollment
Region of Enrollment(participants)Trastuzumab Deruxtecan (T-DXd)Trastuzumab+CapecitabineLapatinib+CapecitabineTotal
United States4114964
Czechia1203
Japan4661870
United Kingdom274435
Spain298744
Greece93214
South Korea66111794
Turkey3612452
Belgium4105
Brazil4110859
Italy3331753
Israel140418
France3781257
Australia107421
Germany122519
08

Study locations

227 sites
  • Ironwood Cancer Research Centers
    Chandler, Arizona 85224, United States
  • UCLA Hematology Oncology - Main Site
    Los Angeles, California 90095, United States
  • Pacific Cancer Care
    Monterey, California 93940, United States
  • Sharp Memorial Hospital
    San Diego, California 92123, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut 06510, United States
  • Washington Cancer Institute
    Washington D.C., District of Columbia 20010, United States
  • Florida Cancer Specialists-Broadway
    Fort Myers, Florida 33901, United States
  • Piedmont Cancer Institute, PC
    Atlanta, Georgia 30318, United States
  • Kapiolani Medical Center for Women and Children/Univ of HI
    Honolulu, Hawaii 96826, United States
  • Loyola University Health System
    Maywood, Illinois 60153, United States
  • Community Hospital
    Munster, Indiana 46321, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • Maine Center for Cancer Medicine
    Scarborough, Maine 04074, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Cornell-Beshore Cancer Institute
    Joplin, Missouri 64804, United States
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111, United States
  • Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC
    Kansas City, Missouri 64132, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • North Shore Hematology Oncology Associates, PC
    East Setauket, New York 11733, United States
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
    New York, New York 10065, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • Cleveland Clinic Main Campus
    Cleveland, Ohio 44195, United States
  • The Ohio State University
    Columbus, Ohio 43235, United States
  • Dayton Physicians, LLC
    Kettering, Ohio 45409, United States
  • Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • UPMC Cancer Center
    Pittsburgh, Pennsylvania 15213, United States
  • Tennessee Oncology, PLLC Chattanooga
    Chattanooga, Tennessee 37404, United States
  • The West Clinic
    Germantown, Tennessee 38138, United States
  • SCRI - Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • The Methodist Hospital Research Institute
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Tyler
    Tyler, Texas 75708, United States
  • Community Cancer Trials of Utah
    Ogden, Utah 84405, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • St Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Macquarie University Hospital
    Sydney, New South Wales 2109, Australia
  • The Tweed Hospital
    Tweed Heads, New South Wales 2485, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Ashford Cancer Centre Research
    Kurralta Park, South Australia 5037, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Peninsula and South Eastern Haematology & Oncology Group
    Frankston, Victoria 3199, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Sunshine Hospital
    Saint Albans, Victoria 3021, Australia
  • South West Oncology
    Warrnambool, Victoria 3280, Australia
  • Ballarat Oncology & Haematology Service
    Wendouree, Victoria 3355, Australia
  • St John of God Subiaco Hospital
    Subiaco, Western Australia 6008, Australia
  • Calvary North Adelaide Hospital
    Bruce, 2614, Australia
  • Universitair Ziekenhuis Brussel
    Brussels, 1090, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • AZ Maria Middelares
    Ghent, 9000, Belgium
  • Az Groeninge
    Kortrijk, 8500, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU UCL Namur site de Sainte Elisabeth
    Namur, 5000, Belgium
  • Pronutrir
    Fortaleza, Ceará 60810-180, Brazil
  • NOB - Núcleo de Oncologia da Bahia
    Salvador, Estado de Bahia 40170-110, Brazil
  • AMO - Assistência Multidisciplinar em Oncologia
    Salvador, Estado de Bahia 41950-640, Brazil
  • Oncobio Servicos de Saude
    Nova Lima, Minas Gerais 34000, Brazil
  • HGB - Hospital Giovanni Battista - Mãe de Deus Center
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
  • CliniOnco - Tratamento Integrado do Câncer
    Porto Alegre, Rio Grande do Sul 90430-090, Brazil
  • Escosteguy Barrios, Carlos Henrique
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Hospital Nossa Senhora da Conceição
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Clínica de Neoplasias Litoral Ltda.
    Itajaí, Santa Catarina 88301-220, Brazil
  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
    Santo André, São Paulo 09060-650, Brazil
  • IBCC - Instituto Brasileiro de Controle do Câncer
    São Paulo, São Paulo 03102-002, Brazil
  • COI - Clínicas Oncológicas Integradas
    Rio de Janeiro, 22793-080, Brazil
  • Sociedade Beneficiente de Senhoras Hospital Sírio Libanês
    São Paulo, 01308, Brazil
  • A. C. Camargo Cancer Center
    São Paulo, 01509-900, Brazil
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Fakultni nemocnice v Motole
    Prague, 150 06, Czechia
  • Nemocnice Na Bulovce
    Prague, 180 81, Czechia
  • Hôpital Nord - CHU Marseille
    Marseille, Bouches-du-Rhône 13915, France
  • Centre François Baclesse
    Caen, Calvados 14076, France
  • CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
    Plérin, Cotes d'Armor 22190, France
  • Centre Georges François Leclerc
    Dijon, Côte-d'Or 21079, France
  • CHU Besançon - Hôpital Jean Minjoz
    Besançon, Doubs 25030, France
  • CHU Brest - Hôpital Morvan
    Brest, Finistere 29609, France
  • Hôpital Privé d'Antony
    Antony, Hauts De Seine 92160, France
  • Centre René Huguenin
    Saint-Cloud, Hauts De Seine 92110, France
  • Clinique Clementville
    Montpellier, Herault 34070, France
  • Institut Régional du Cancer de Montpellier
    Montpellier, Herault 34298, France
  • CRLCC Eugene Marquis
    Rennes, Ille Et Vilaine 35042, France
  • Centre Oscar Lambret
    Lille, Nord 59020, France
  • Centre de cancerologie les Dentellieres
    Valenciennes, Nord 59300, France
  • Institut Curie - site de Paris
    Paris, Paris 75005, France
  • Centre Hospitalier de la côte Basque
    Bayonne, Pyrenees Atlantiques 64109, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, Rhone 69495, France
  • Clinique Victor Hugo - Centre Jean Bernard
    Le Mans, Sarthe 72015, France
  • Centre Henri Becquerel
    Rouen, Seine Maritime 76038, France
  • Institut Sainte Catherine
    Avignon, Vaculuse 84918, France

Showing the first 100 of 227 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Andre F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20. PubMed 37086745 ↗
  • Fehm T, Cottone F, Dunton K, Andre F, Krop I, Park YH, De Laurentiis M, Miyoshi Y, Armstrong A, Borrego MR, Yerushalmi R, Duhoux FP, Takano T, Lu W, Egorov A, Kim SB. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024 May;25(5):614-625. doi: 10.1016/S1470-2045(24)00128-1. PubMed 38697155 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Jun 2022, 46 months.

Results were first posted in Jun 2023, 11 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 46 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2018
First posted
May 14, 2018
StartActual
Aug 1, 2018
Primary completionActual
Jun 30, 2022
CompletionActual
Dec 23, 2025
Results first posted
Jun 26, 2023
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03523585
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
May 14, 2018
Start date
Aug 1, 2018
Primary completion
Jun 30, 2022
Completion
Dec 23, 2025
Results posted
Jun 26, 2023
Last update
Feb 27, 2026

Study contacts

Global Team Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion